Clinical Trials Logo

Clinical Trial Details — Status: Terminated

Administrative data

NCT number NCT03339726
Other study ID # CO-170302131230-URCT
Secondary ID
Status Terminated
Phase Phase 2
First received
Last updated
Start date November 30, 2017
Est. completion date April 16, 2018

Study information

Verified date June 2019
Source Johnson & Johnson Consumer and Personal Products Worldwide
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This will be a randomized, double-blind, placebo controlled, parallel-group Phase 2 study to evaluate the efficacy of a new formulation of phenylephrine HCl and a currently marketed phenylephrine HCl for relief of nasal congestion in subjects with naturally occurring cold symptoms.


Recruitment information / eligibility

Status Terminated
Enrollment 193
Est. completion date April 16, 2018
Est. primary completion date April 16, 2018
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility 1. Provide a signed and dated informed consent form before any study-related procedures.

2. Men or non-pregnant, non-lactating women, aged 18 years or older, who have cold symptoms due to an acute upper respiratory tract infection but are otherwise healthy

3. Have experienced onset of common cold symptoms (per subject report) within 72 hours before study entry consisting of cold symptoms per the following:

1. At Visit 1, at least moderate severity (score = 5, on a scale from 0 = none to 7 = severe) for stuffy/congested nose, and

2. At Visit 1, at least mild (score = 3, on a scale from 0 = none to 7 = severe) for sinus pressure/tenderness, and

3. Within the past 72 hours, two or more of the following symptoms: runny nose, sore or scratchy throat, sneezing, headache, malaise, or cough.

4. Are normotensive and have no clinically significant abnormalities identified by medical history or vital sign measurement (except as consistent with the diagnosis of the common cold) as determined by the Investigator at screening.

- Blood pressure must be within the following limits after sitting for approximately 5 minutes: > 90 and <140 mm Hg systolic, and >50 and <90 mm Hg diastolic, at screening

- Pulse rate >50 and <90 beats/minute at screening;

- Body Mass Index (BMI) of 18 to 34 kg/m2 (inclusive);

5. Willing to use only the study treatment for cold symptom relief during the course of the study and avoid the use of treatments that may affect nasal / cold symptomatology; no other cough, cold, allergy, or analgesic/antipyretic medicines (non-prescription or prescription) or herbal/dietary supplements will be permitted during the study

6. Females of childbearing potential must have used an effective form of birth control for three months before Screening and a negative urine pregnancy test at the Screening visit.

7. Female and male subjects must agree to the contraceptive requirement use during the study and for at least 30 days after the last dose (for females) (See Section 10.4.3 ).

8. Willing and able to comply with the study procedures and visit schedule, which includes remaining at the study site for at least 4 hours after the first dose of study medicine on Day 1.

9. Able to read and understand English and/or French;

Exclusion criteria:

1. Currently experiencing nasal congestion due to allergic rhinitis or chronic respiratory disease.

2. Any ear, nose, throat, or respiratory tract disease, other than the common cold, identified by signs and symptoms reported by the subject, or by medical history or medication history

3. Presence of asthma.

4. History of rhinitis medicamentosa, anatomical nasal obstruction or deformity, nasal reconstructive surgery, or chronic sleep apnea.

5. Fever of = 101.0 °F (38.3 °C).

6. Heart disease, controlled or uncontrolled hypertension, thyroid disease, diabetes, glaucoma, prostatic hypertrophy, or presence of a disease, which in the opinion of the investigator, would preclude the use of phenylephrine.

7. Are currently taking, or have taken within two weeks of screening, a monoamine oxidase inhibitor (MAOI).

8. Have the need to use medications which may impact nasal symptomatology i.e. systemic, inhaled (oral or nasal) corticosteroids, and the following drugs with significant anticholinergic properties: tricyclic antidepressants, paroxetine, medicines used to treat overactive bladder, antipsychotic medication, skeletal muscle relaxants, antiparkinsonian medication, the anticonvulsants carbamazepine and oxcarbazepine, and dicycloverine (dicyclomine), dimenhydrinate, propantheline, atropine, hyoscyamine, belladonna, prochlorperazine and promethazine.

9. Have a bacterial sinus infection within 2 weeks prior to screening.

10. Use of systemic antibiotics within the past 7 days prior to screening.

11. Known or suspected alcohol or substance abuse (e.g., amphetamines, benzodiazepines, cocaine, marijuana, opiates).

12. Use of marijuana containing substances within the 10 days prior to screening and throughout the study.

13. Positive Urine Drug Screen.

14. Use of alcohol throughout the study.

15. History of smoking tobacco products or use of nicotine-containing substances within the previous three months as determined by subject's medical history or subject's verbal report.

16. Known sensitivity to the investigational product or any excipients of the drug product.

17. Before the first dose of study medicine, use of

1. oral or intranasal cold, cough, allergy, or analgesic/antipyretic medicines within approximately 12 hours;

2. menthol products, medicated lozenge, humidifier, nasal saline spray or throat spray within approximately 6 hours;

3. herbal/dietary supplements within approximately 12 hours.

18. Have difficulty swallowing tablets/capsules or are unable to swallow whole without crushing, chewing, splitting, or dissolving.

19. Subjects who were previously randomized and received the IP.

20. Significant unstable or uncontrolled medical condition that may interfere with a subject's participation in the study.

21. Other severe, acute or chronic, medical or psychiatric condition(s) or laboratory abnormality that may increase the risk associated with study participation or IP administration or may interfere with the interpretation of study results and, in the judgment of the investigator, would make the subject inappropriate for entry into this study.

22. Currently participating in another clinical trial or has done so in the past 30 days.

23. Subjects who are related to those persons involved directly or indirectly with the conduct of this study (i.e., principal investigator, sub-investigators, study coordinators, other site personnel, employees of Johnson & Johnson (J&J) subsidiaries, contractors of J&J, and the families of each).

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
New Formulation Phenylephrine HCl
2 doses of one tablet 12 hours apart
Marketed Phenylephrine HCl
4 doses of one capsule 4 hours apart
Placebo
4 doses of placebo capsule and tablet taken 4 hours apart

Locations

Country Name City State
Canada Dawson Road Family Medical Clinic Guelph Ontario
Canada The Medical Arts Health Research Group Kelowna British Columbia
Canada Sunningdale Health and Wellness Centre London Ontario
Canada Mission Hills Urgent Care Walk in Clinic Mission British Columbia
Canada Bluewater Clinical Research Group, Inc. Sarnia Ontario
Canada Diex Recherche Sherbrooke Quebec
Canada NEOMO Research Sudbury Ontario
Canada Canadian Phase Onward, Inc. Toronto Ontario
Canada PrimeHealth Clinical Research Toronto Ontario
Canada James Lai, MD, Inc Vancouver British Columbia
Canada Diex Recherche Victoriaville Quebec

Sponsors (1)

Lead Sponsor Collaborator
Johnson & Johnson Consumer Inc. (J&JCI)

Country where clinical trial is conducted

Canada, 

Outcome

Type Measure Description Time frame Safety issue
Primary Mean Change From Baseline in the Nasal Congestion Severity Score Average change from baseline in the Nasal Congestion Severity Score on an 8 point scale with 0=None and 7=Severe. Change from baseline in the Nasal Congestion Severity Score averaged over assessments at 2, 4, 6, 8, 10, and 12 hours. 0-12 hours
Secondary Average Change From Baseline in the Nasal Congestion Severity Score Average change from baseline in the Nasal Congestion Severity Score averaged over hours 8-12. This is an 8 point scale with 0=None and 7=Severe. 0-12 hours
Secondary Change From Baseline in the Nasal Congestion Severity Score Change from baseline in the Nasal Congestion Severity Score at 2 hours. This is an 8 point scale with 0=None and 7=Severe. 0-2 hours
Secondary Change From Baseline in the Nasal Congestion Severity Score Change from baseline in the Nasal Congestion Severity Score at 4 hours. This is an 8 point scale with 0=None and 7=Severe. 0-4 hours
Secondary Change From Baseline in the Nasal Congestion Severity Score Change from baseline in the Nasal Congestion Severity Score at 6 hours. This is an 8 point scale with 0=None and 7=Severe. 0-6 hours
Secondary Change From Baseline in the Nasal Congestion Severity Score Change from baseline in the Nasal Congestion Severity Score at 8 hours. This is an 8 point scale with 0=None and 7=Severe. 0-8 hours
Secondary Change From Baseline in the Nasal Congestion Severity Score Change from baseline in the Nasal Congestion Severity Score at 10 hours. This is an 8 point scale with 0=None and 7=Severe. 0-10 hours
Secondary Change From Baseline in the Nasal Congestion Severity Score Change from baseline in the Nasal Congestion Severity Score at 12 hours. This is an 8 point scale with 0=None and 7=Severe. 0-12 hours
Secondary Change From Baseline in the Nasal Congestion Severity Score Change from baseline in the Nasal Congestion Severity Score at 24 hours. This is an 8 point scale with 0=None and 7=Severe. 0-24 hours
Secondary Average Change From Baseline in Sinus Pressure/Tenderness Scores Change from baseline in Sinus Pressure/Tenderness Scores averaged over assessments at 2, 4, 6, 8, 10, and 12 hours. This is an 8 point scale with 0=None and 7=Severe. 0-12 hours
Secondary Change From Baseline in Sinus Pressure/Tenderness Scores Change from baseline in Sinus Pressure/Tenderness Scores at 2 hours. This is an 8 point scale with 0=None and 7=Severe. 0-2 hours
Secondary Change From Baseline in Sinus Pressure/Tenderness Scores Change from baseline in Sinus Pressure/Tenderness Scores at 4 hours. 0-4 hours
Secondary Change From Baseline in Sinus Pressure/Tenderness Scores Change from baseline in Sinus Pressure/Tenderness Scores at 6 hours. This is an 8 point scale with 0=None and 7=Severe. 0-6 hours
Secondary Change From Baseline in Sinus Pressure/Tenderness Scores Change from baseline in Sinus Pressure/Tenderness Scores at 8 hours. This is an 8 point scale with 0=None and 7=Severe. 0-8 hours
Secondary Change From Baseline in Sinus Pressure/Tenderness Scores Change from baseline in Sinus Pressure/Tenderness Scores at 10 hours. This is an 8 point scale with 0=None and 7=Severe. 0-10 hours
Secondary Change From Baseline in Sinus Pressure/Tenderness Scores Change from baseline in Sinus Pressure/Tenderness Scores at 12 hours. This is an 8 point scale with 0=None and 7=Severe. 0-12 hours
Secondary Change From Baseline in Sinus Pressure/Tenderness Scores Change from baseline in Sinus Pressure/Tenderness Scores at 24 hours. This is an 8 point scale with 0=None and 7=Severe. 0-24 hours
See also
  Status Clinical Trial Phase
Completed NCT05269290 - Efficacy and Safety of Ingavirin®, Syrup, 30 mg/5 ml, in Children With Influenza and Other Acute Respiratory Viral Infections Phase 3
Completed NCT02451163 - DBRCT on the Effect of Wheat Polysaccharides on Common Cold Infections in Elderly Phase 2
Completed NCT01944631 - Iota-Carrageenan Nasal Spray in Common Cold Phase 4
Completed NCT01651715 - Efficacy and Safety Study of Homeopathic Oral Antibodies to Treat Viral Upper Respiratory Tract Infections Phase 1/Phase 2
Completed NCT00963443 - Acetylsalicylic Acid Combined With Pseudoephedrine in Common Cold Phase 3
Completed NCT00778648 - Encapsulated Juice Powder Concentrate for Preventing Common Cold Symptoms N/A
Completed NCT00065715 - Echinacea Versus Placebo Effect in Common Cold (Physician Echinacea Placebo) Phase 3
Completed NCT00032500 - Evaluation of Echinacea for the Common Cold Phase 2
Not yet recruiting NCT05070650 - Efficacy and Safety of the Combination of Acetylcysteine, Paracetamol and Phenylephrine for the Treatment of Common Cold Phase 3
Completed NCT04144491 - Effect of L. Rhamnosus Yoba on RTI and Other Health Outcomes Among Children (3-6 Years) in Uganda N/A
Not yet recruiting NCT04073511 - Herbal Medicine 'Eungyosan' and 'Samsoeum' for Common Cold N/A
Completed NCT03189537 - Study of Post-Exposure Ingavirin® Prophylaxis of Influenza and Acute Respiratory Viral Infections Phase 3
Terminated NCT01964885 - Benefit and Tolerability of IQP-AS-105 in Reducing Susceptibility to Upper Respiratory Tract Infections Phase 3
Completed NCT01277081 - Effect of Paracetamol on the Common Cold Phase 2
Completed NCT01728090 - Effectiveness of a Handwashing Programme in the Prevention of School Absenteeism Due to Respiratory Infections Phase 4
Completed NCT00405509 - The Natural History of Viral Upper Respiratory Infections in Children Aged 6 to Less Than 14 Years N/A
Completed NCT01033526 - Symptomatic Treatment of Common Cold Symptoms Phase 4
Completed NCT05556148 - Otrivine: Quality of Life (QoL) Impact in a Real-World Setting Phase 4
Completed NCT01361399 - Active and Placebo Controlled Study to Test the Efficacy and Safety of an Aspirin-Lidocaine Lozenge in the Symptomatic Treatment of Sore Throat Associated With a Common Cold Phase 3
Recruiting NCT05244148 - Two Seawater-based Formulations for Relief of Nasal Congestion in Paediatric Subjects N/A